MedPath

Fluzone

Generic Name
Fluzone
Clinical Trials
Related News

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Early Phase 1
Recruiting
Conditions
Skin Cancer
Cutaneous Squamous Cell Carcinoma (CSCC)
Cutaneous Squamous Cell Cancer
Interventions
First Posted Date
2024-10-29
Last Posted Date
2025-01-16
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
25
Registration Number
NCT06664151
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

Phase 3
Active, not recruiting
Conditions
Influenza
Interventions
Biological: Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
First Posted Date
2024-10-15
Last Posted Date
2025-02-14
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
1178
Registration Number
NCT06641180
Locations
🇺🇸

CenExel CNS- Site Number : 8400005, Los Alamitos, California, United States

🇺🇸

Alliance for Multispeciality Research - Fort Myers- Site Number : 8400019, Fort Myers, Florida, United States

🇺🇸

Research Centers of America - Hollywood- Site Number : 8400010, Hollywood, Florida, United States

and more 17 locations

Vaccine Responses in Patients With B Cell Malignancies

Phase 4
Recruiting
Conditions
Lymphoma
Interventions
Biological: Heplisav -B
Biological: Pfizer-COVID-19 Vaccine
Biological: FluLaval
Drug: AREXVY, ABRYSVO
First Posted Date
2021-12-28
Last Posted Date
2025-04-10
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
500
Registration Number
NCT05170399
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Phase 4
Recruiting
Conditions
Influenza
Interventions
First Posted Date
2019-09-24
Last Posted Date
2024-07-11
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
50
Registration Number
NCT04101838
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children

Phase 4
Completed
Conditions
Influenza
Interventions
First Posted Date
2016-08-18
Last Posted Date
2024-11-21
Lead Sponsor
McMaster University
Target Recruit Count
3425
Registration Number
NCT02871206
Locations
🇨🇦

McMaster University, Hamilton, Ontario, Canada

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients

Phase 1
Completed
Conditions
Influenza
Gammopathy
Interventions
First Posted Date
2014-10-17
Last Posted Date
2016-08-25
Lead Sponsor
Yale University
Target Recruit Count
51
Registration Number
NCT02267733
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

Strategies for Enhancing Mucosal Immunity to Influenza Vaccine

Early Phase 1
Completed
Conditions
Mucosal Immunity
Interventions
First Posted Date
2011-06-30
Last Posted Date
2012-12-06
Lead Sponsor
John Sundy
Target Recruit Count
60
Registration Number
NCT01385215
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy